Cure8 research brief
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by broader evidence.
Clinicians treating UC, researchers studying biologic therapies or IL-23 pathway drugs, and patients with moderate-to-severe UC (including those considering or on biologic therapies).
The authors searched major databases and used outcome data from two randomized trial programs (a Phase 2 program and the Phase 3 LUCENT program) including ClinicalTrials.gov results. Mirikizumab increased clinical remission, clinical response, endoscopic remission, symptomatic remission, and histologic remission compared with placebo in pooled analyses.
Serious adverse events were reported less often with mirikizumab than placebo in both induction and maintenance analyses. The review is based on two independent randomized-programs only, so some pooled estimates (especially induction outcomes) have wider confidence intervals and moderate-to-high heterogeneity driven by the smaller Phase 2 trial.
This limits certainty and suggests results should be interpreted with caution while awaiting broader real-world and longer-term data.
The meta-analysis includes only two RCT programs (Phase 2 and LUCENT Phase 3). Some outcomes had wider confidence intervals or heterogeneity, so findings are promising but provisional pending larger and longer-term data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
